ORMP
Price
$2.31
Change
+$0.01 (+0.43%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
93.12M
34 days until earnings call
PULM
Price
$6.11
Change
+$0.13 (+2.17%)
Updated
Jan 22 closing price
Capitalization
22.32M
63 days until earnings call
Ad is loading...

ORMP vs PULM

Header iconORMP vs PULM Comparison
Open Charts ORMP vs PULMBanner chart's image
Oramed Pharmaceuticals
Price$2.31
Change+$0.01 (+0.43%)
Volume$574
Capitalization93.12M
Pulmatrix
Price$6.11
Change+$0.13 (+2.17%)
Volume$8.06K
Capitalization22.32M
ORMP vs PULM Comparison Chart
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORMP vs. PULM commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and PULM is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (ORMP: $2.31 vs. PULM: $6.11)
Brand notoriety: ORMP and PULM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 42% vs. PULM: 6%
Market capitalization -- ORMP: $93.12M vs. PULM: $22.32M
ORMP [@Biotechnology] is valued at $93.12M. PULM’s [@Biotechnology] market capitalization is $22.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 0 FA rating(s) are green whilePULM’s FA Score has 1 green FA rating(s).

  • ORMP’s FA Score: 0 green, 5 red.
  • PULM’s FA Score: 1 green, 4 red.
According to our system of comparison, PULM is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 3 TA indicator(s) are bullish while PULM’s TA Score has 4 bullish TA indicator(s).

  • ORMP’s TA Score: 3 bullish, 3 bearish.
  • PULM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ORMP and PULM are a good buy in the short-term.

Price Growth

ORMP (@Biotechnology) experienced а -1.28% price change this week, while PULM (@Biotechnology) price change was +2.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

ORMP is expected to report earnings on May 28, 2025.

PULM is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($93.1M) has a higher market cap than PULM($22.3M). ORMP YTD gains are higher at: -4.545 vs. PULM (-12.464). ORMP has higher annual earnings (EBITDA): 9.44M vs. PULM (-6.78M). ORMP has more cash in the bank: 142M vs. PULM (10.8M). PULM has less debt than ORMP: PULM (0) vs ORMP (429K). PULM has higher revenues than ORMP: PULM (10M) vs ORMP (0).
ORMPPULMORMP / PULM
Capitalization93.1M22.3M417%
EBITDA9.44M-6.78M-139%
Gain YTD-4.545-12.46436%
P/E Ratio21.00N/A-
Revenue010M-
Total Cash142M10.8M1,315%
Total Debt429K0-
FUNDAMENTALS RATINGS
ORMP vs PULM: Fundamental Ratings
ORMP
PULM
OUTLOOK RATING
1..100
7570
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8598
PRICE GROWTH RATING
1..100
5834
P/E GROWTH RATING
1..100
53100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PULM's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for ORMP (66) in the Pharmaceuticals Other industry. This means that PULM’s stock grew somewhat faster than ORMP’s over the last 12 months.

PULM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that PULM’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as PULM (98) in the Biotechnology industry. This means that ORMP’s stock grew similarly to PULM’s over the last 12 months.

PULM's Price Growth Rating (34) in the Biotechnology industry is in the same range as ORMP (58) in the Pharmaceuticals Other industry. This means that PULM’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for PULM (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than PULM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPPULM
RSI
ODDS (%)
N/A
Bearish Trend 16 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 16 days ago
79%
Momentum
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 16 days ago
77%
MACD
ODDS (%)
Bearish Trend 16 days ago
67%
Bearish Trend 16 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 16 days ago
81%
Bearish Trend 16 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
84%
Bullish Trend 16 days ago
75%
Advances
ODDS (%)
Bullish Trend 18 days ago
82%
Bullish Trend 22 days ago
70%
Declines
ODDS (%)
Bearish Trend 16 days ago
84%
Bearish Trend 16 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 16 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 16 days ago
79%
View a ticker or compare two or three
Ad is loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVST21.050.50
+2.43%
Envista Holdings Corp
FNV129.90-0.76
-0.58%
Franco-Nevada Corp
PRLB39.86-0.24
-0.60%
Proto Labs
MHLD1.10-0.04
-3.51%
Maiden Holdings Ltd
APCX0.43-0.04
-8.90%
AppTech Payments Corp

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+0.43%
BTAI - ORMP
44%
Loosely correlated
+1.54%
INO - ORMP
44%
Loosely correlated
+2.27%
MBIO - ORMP
44%
Loosely correlated
-3.70%
VERV - ORMP
44%
Loosely correlated
+18.72%
ZNTL - ORMP
43%
Loosely correlated
+0.44%
More

PULM and

Correlation & Price change

A.I.dvisor indicates that over the last year, PULM has been loosely correlated with ORMP. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if PULM jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PULM
1D Price
Change %
PULM100%
+2.17%
ORMP - PULM
33%
Loosely correlated
+0.43%
INM - PULM
30%
Poorly correlated
-20.79%
GERN - PULM
27%
Poorly correlated
+1.01%
TSHA - PULM
26%
Poorly correlated
N/A
PMVP - PULM
25%
Poorly correlated
-2.22%
More